Reata Pharmaceuticals Ownership
| RETADelisted Stock | USD 109.67 3.31 2.93% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Reata |
Reata Stock Ownership Analysis
About 88.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 2.62. Reata Pharmaceuticals had not issued any dividends in recent years. Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas. Reata Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 346 people. To find out more about Reata Pharmaceuticals contact Warren Huff at 972 865 2219 or learn more at https://www.reatapharma.com.Reata Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Reata Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Reata Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Reata Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Michael Wortley over a year ago Disposition of 49701 shares by Michael Wortley of Reata Pharmaceuticals subject to Rule 16b-3 | ||
Michael Wortley over a year ago Sale by Michael Wortley of 807 shares of Reata Pharmaceuticals | ||
Michael Wortley over a year ago Acquisition by Michael Wortley of 4125 shares of Reata Pharmaceuticals subject to Rule 16b-3 | ||
Michael Wortley over a year ago Sale by Michael Wortley of 894 shares of Reata Pharmaceuticals | ||
Michael Wortley over a year ago Sale by Michael Wortley of 414 shares of Reata Pharmaceuticals | ||
Michael Wortley over a year ago Acquisition by Michael Wortley of 63650 shares of Reata Pharmaceuticals subject to Rule 16b-3 |
Reata Pharmaceuticals Outstanding Bonds
Reata Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Reata Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Reata bonds can be classified according to their maturity, which is the date when Reata Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| O 5625 13 OCT 32 Corp BondUS756109BP80 | View | |
| O 505 13 JAN 26 Corp BondUS756109BQ63 | View | |
| O 485 15 MAR 30 Corp BondUS756109BR47 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Other Consideration for investing in Reata Stock
If you are still planning to invest in Reata Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Reata Pharmaceuticals' history and understand the potential risks before investing.
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| CEOs Directory Screen CEOs from public companies around the world |